CD22 and acute lymphoblastic leukemia: The in vivo antitumor efficacy of the bi-specific CD19-CD22 CAR-T cells was evaluated using a Nalm6-bearing B-ALL xenograft model, benchmarked against negative controls and single-target CD19 or CD22 groups.